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Abstract: 
Aim: To evaluate the efficacy and safety of the augmentation of clozapine with aripiprazole in patients with treatment-
resistant schizoaffective and psychotic bipolar disorders in a retrospective manner. Pharmacodynamic and pharmacoki-
netic interactions between the two drugs were also investigated. 
Patients: Three men and 4 women (median age 36 and 40 years, respectively) who had mean scores at BPRS and CGI-
Severity of 59.1±12.0 and 5.4±0.5, respectively, were treated with clozapine (mean dose 292.9±220.7 mg/day). Patients 
received an adjunctive treatment with aripiprazole (mean dose 6.8 ± 3.7 mg/day). Clozapine, norclozapine and aripipra-
zole plasma levels were measured by means of a high performance liquid chromatograpy with UV detection. 
Results: Total scores at BPRS decreased significantly (from 59.1±12.0 to 51.1±15.6, p=0.007) after aripirazole augmenta-
tion. In particular, the factors “thought disorder” (from 10.4±4.4 to 9.0±4.5, p=.047) and “anergia” (from 10.0±2.7 to 
8.0±2.4, p=.018) significantly improved. Concomitant administration of aripiprazole and clozapine did not result in an in-
crease in side effects over the period of treatment. Dose-normalized plasma levels of both clozapine and norclozapine  and 
the clozapine/norclozapine metabolic ratio in all patients did not vary as well. 
Conclusion: The augmentation of clozapine with aripirazole was safe and effective in severe psychotic schizoaffective and 
bipolar disorders which failed to respond to atypical antipsychotics. A possible pharmacokinetic interaction between clo-
zapine and aripiprazole does not account for the improved clinical benefit obtained after aripiprazole augmentation. 
Keywords: Psychotic bipolar disorder, schizoaffective disorder, clozapine, aripiprazole, augmentation, pharmacokinetic inter-
actions. 
INTRODUCTION 
Severe forms of psychotic mood disorders may be char-
acterized by psychotic manifestations typically schizo-
phrenic (first-rank symptoms), or residual negative symp-
toms and deterioration of functioning [1, 2, 3]. Such clinical 
pictures, often labelled schizoaffective, represent intermedi-
ate syndromes between typical bipolar disorder and typical 
schizophrenia. They are frequently treatment-resistant to 
classical mood-stabilizers so that a maintenance treatment 
with antipsychotics is often considered [4]. Actually, these 
patients undergo complex treatment regimens, which may 
include the co-administration or more mood-stabilizer and 
one or more first- or second-generation antipsychotics. Clo-
zapine, the “gold standard” of second-generation antipsy- 
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chotics, has not been approved for the treatment of bipolar 
disorder, though it has showed its efficacy in acute mania [5] 
and in the prevention of recurrences of severe psychotic bi-
polar disorders [6]. Aripiprazole, which is a partial agonist at 
D2 and 5-HT1A receptors while exerts antagonist activity 
against 5-HT2A receptors, has been approved by FDA for the 
maintenance treatment after a manic or mixed episode. 
The combination of clozapine and aripiprazole in treat-
ment-resistant psychoses is effective and well-tolerated ac-
cording to a recent review [7]. However, large studies are not 
yet available and the majority of the published researches are 
confounded by several methodologic flaws. A large, ran-
domized, multicenter trial is ongoing in Italy to test the effi-
cacy of clozapine – aripiprazole combination compared to 
clozapine – haloperidol combination [8]. 
Recently, a double-bind placebo controlled trial of 
aripiprazole augmentation of clozapine, reported no signifi-
cant improvement of total symptom severity but a favorable Aripirazole-clozapine Combination in Psychotic Mood Disorders  Clinical Practice & Epidemiology in Mental Health, 2010, Volume 6    31 
change in the negative symptomatology in a sample of 62 
patients with schizophrenia [9]. 
These data appear to be in line with case reports and 
open-label trials suggesting that this combined treatment 
may improve residual and negative symptoms in schizophre-
nia with no change in clozapine serum levels after admini-
stration of aripiprazole [10-16]. In fact, the two drugs have 
different metabolic pathways, therefore no relevant interac-
tions are expected to occur, although other pharmacokinetic 
interactions could also be possible but not yet explored.  
Since no studies have tested such a treatment strategy in 
schizoaffective or severe psychotic bipolar disorder, we 
aimed at evaluating in a retrospective fashion the efficacy 
and the safety of augmentation of clozapine with aripiprazole 
in those kind of patients, and to assess any possible pharma-
cokinetic interaction between the two drugs.  
MATERIALS AND METHODOLOGY 
Patients 
Medical records of adult inpatients with a diagnosis of 
schizoaffective or psychotic bipolar disorders (according to 
DSM-IV criteria [17]) and treated with clozapine and 
aripiprazole were retrospectively and thoroughly examined 
referring to a six month period before enrolment in the study. 
All patients were hospitalized in the Wards of the Depart-
ment of Psychiatry, at the University of Pisa, where a num-
ber of therapeutical monitoring protocols are active. These 
include the administration of rating scales, the recording of 
side effects, laboratory tests and measurement of drug levels. 
Eligibility criteria were: 1) age within the range 18-65 
years, 2) failure of at least two trials with different classical 
mood stabilizers, and/or with antipsychotics 3) administra-
tion of clozapine for at least six months at the most tolerated 
dosage, 4) persistent positive, negative or depressive symp-
toms, or relevant mood swings (despite the use of clozapine), 
5) eligibility for aripiprazole augmentation and 6) registra-
tion of plasma levels of clozapine and aripiprazole beacause 
of the application of therapeutic drug monitoring protocols 
for both drugs. Further inclusion criteria were: 7) normal 
values of bone marrow, hepatic and renal functions, 8) capa-
bility to attend the follow up visits, 9) proved compliance. 
Exclusion criteria included: 1) positive case history of drug 
abuse, 2) Parkinson’s disease, 3) epilepsy, 4) myasthenia 
gravis, 5) current major depression, 6) jaundice or hemato-
logical diseases, 7) photosensitization, 8) pregnancy or 
breast-feeding. Smoking habits were recorded for each pa-
tient, while the administration of other - antipsychotic, mood 
stabilizers, or antidepressant - drugs were allowed.  
Clozapine and norclozapine plasma levels recorded 
within patients’ case report forms were considered for the 
aims of the present work at the day before (T1) and 15 days 
after (T2) aripiprazole administration. On the contrary, 
aripiprazole plasma levels measured at least ten days after 
the first administration (T2) were considered suitable for the 
present study. In particular, the therapeutic monitoring pro-
tocols adopted in our clinic were based on the measurement 
of plasma drug levels three hours after clozapine and 
aripiprazole morning dose, which corresponds approximately 
to the time of peak concentration of both drugs, in fasting 
conditions.  
ECG, safety hematology, including complete blood count 
and blood chemistry tests for liver function were performed 
on admission and during adjunctive treatment according to 
our routine protocols. Unwanted effects were assessed by 
evaluating patients at baseline and at T2. Seven patients were 
required in order to detect an increase of  25% in the mean 
values of clozapine’s plasma concentration before and after 
augmentation with aripiprazole, with 80% power at a 5% 
level of statistical significance, and when a standard devia-
tion of 20% of mean values was assumed. 
All patients provided written consent to the revision of 
their case histories, and the study was authorized by the local 
Ethics Committee.  
Evaluation of the Disease, Treatment Efficacy and   
Tolerability 
Before the administration of aripiprazole (T1) and 15 
days after the augmentation (T2), characteristics and severity 
of patients’ disease, together with treatment effectiveness 
evaluated according to the Brief Psychiatric Rating Scale-24 
items (BPRS; [18]) and Clinical Global Impression (CGI; 
[19]) scales were recorded. Furthermore, any side effect oc-
curred during the study was evaluated in the Dosage Record 
and Treatment Emergent Symptom Scale (DOTES; [20]). 
Laboratory Analysis 
Therapeutic drug monitoring protocols provided that, 
blood samples (5 ml) were withdrawn from a peripheral vein 
of the forearm, collected within heparinized tubes and im-
mediately centrifuged. Plasma was stored at -20 °C until the 
measurement of drug levels.  
Plasma concentrations of clozapine and its active me-
tabolite were determined by high performance liquid chro-
matography (HPLC) method by using a commercially avail-
able kit (Chromsystems, Munchen, Germany), following the 
instructions of manufacturers. 
The same kit was used, without modifications, for the 
measurement of aripiprazole levels in plasma. In our labora-
tory, the method was proven to be linear for clozapine and 
norclozapine from 10 ng/mL (limit of quantitation) up to 1.5 
g/mL, which widely overlapped the therapeutic range of 
clozapine plasma levels. Furthermore, the method was linear 
from 10 up to 500 g/mL in the case of aripiprazole, which 
could be considered as a temptative therapeutic range when 
the drug is administered at doses up to 30 mg/day [21]. Fi-
nally, the method was characterized by an interday and in-
traday variability lower than 15% for all analytes. 
The clozapine/norclozapine plasma concentration ratio 
was calculated as an index of drug metabolism in patients, 
while levels of the drug and the metabolite were normalized 
by the daily clozapine dose in order to reduce interpatient 
variability because of different daily dosages. 
Statistical Analysis 
Results are expressed as mean value ± standard deviation 
and median. Paired Student’s t test was performed by Inter-
cooled Stata 8.2 [22] to evaluate differences between periods 32    Clinical Practice & Epidemiology in Mental Health, 2010, Volume 6  Benedetti et al. 
of treatment (T1 vs. T2) in clozapine and norclozapine 
plasma levels. A p-value lower than 0.05 was considered to 
be significant. 
RESULTS 
Patients and Treatment Effectiveness 
The enrolment for the study was active from June, 2008 
up to February 2009. During that period of time, 7 patients 
affected by schizoaffective (N=6) or severe psychotic bipolar 
disorders (N=1, patient n. 3) could be included in the study 
according to the inclusion/exclusion criteria. The median age 
was 39 years (range 26-56), 3 patients were men (median 
age, 36 years) and 4 women (median age, 40 years). Before 
aripiprazole augmentation, mean scores at BPRS and CGI-
Severity were 59.1±12.0 and 5.4±0.5, respectively. Table 1 
displays demographic features, doses of clozapine and 
aripiprazole, and of the other drugs, and measures of out-
come (percentages of improvement at BPRS and scores at 
CGI-I) for each patient.  
Before study initiation, patients had been assuming clo-
zapine at a mean dosage of 292.9±220.7 mg/day (range 100-
600 mg/day) for at least one year except for one patient who 
had been assuming clozapine for six months. All patients 
were at the steady state for clozapine and previous controls 
demonstrated very stable plasma concentrations.  
Aripiprazole was added to the previous therapy in order 
to improve symptomatology with doses ranging from 5 to15 
mg/day (mean dose 6.8 ± 3.7 mg/day). 
Concomitant medications did not vary in the study pe-
riod, except for a man who shifted from paroxetine 10 
mg/day to duloxetine 60 mg/day. 
After augmentation with aripiprazole, the mean daily 
dose of clozapine was 269.6±218.4 mg: particularly, in 4 
patients the dose was reduced after 15 days because of the 
improvement of psychotic symtoms. In the remaining 3 sub-
jects, the daily dose was unchanged (Table 1). All patients 
treated with haloperidol had been taking this drug for a 10 to 
30 days period before study initiation. 
The introduction of aripiprazole led to a significant im-
provement in BPRS total score (59.1±12.0 at T1 vs. 
51.1±15.6 at T2, respectively, p=0.007). One patient (male, 
patient number 6) manifested an increase in motor activity 
and agitation four days after the augmentation with aripipra-
zole and we decided to discontinue the add-on treatment. 
Only six patients who remained in the study are included in 
the analyses. 
In particular, the analyses of the 4 BPRS factor scores 
according to Ventura et al. [18] highlighted that the positive 
symptoms factor (including the items  9, 10 11, 12, 14 corre-
sponding to suspiciousness, hallucinations, unusual thought 
content, bizzarre behavior, and disorientation) significantly 
improved ( 16± 5.4 at T1 vs 13.5± 6.5 at T2, t=2.7. p=0.4), 
similarly to the negative symptoms factor (including the 
items 13, 16 17, and 18 corresponding to self-neglecting, 
blunted affect, emotional withdrawal, and motor retardation) 
(10.5± 3.3 at T1 vs 7.8± 2.1  at T2, t=2.8, p=0.4). 
At the section improvement of CGI scale, four patients 
scored 3 (Minimally improved), one scored 4 (No change), 
and two patients scored 1 (very much improved). With these 
Regard, the higher improvement was in the BPRS positive 
and negative symptoms factors for the first patient (respec-
tively 38% and 46%) and in positive symptoms and in mania 
factors for the other (both factors an improvement of 31%). 
Among 4 patients who scored 3 at CGI-I, one had the 
higher improvement in BPRS depression-anxiety factor 
(27%), another in positive and manic symptoms factor (re-
spectively 15% and 14%), two patients had the higher im-
Table 1. Demographic, Clinical Characteristics and Treatments (N=7) 
P  Sex 
Age 
(Years) 
Smoker 
Clozapine T1 
(mg/die) 
Clozapine 
T2 (mg/die) 
Aripiprazole 
(mg/die) 
% of Im-
provement in 
BPRS Total 
Scores 
Scores at 
CGI- I 
(T2) 
Concomitant Medications 
1 
 
F  41  no  600  525  5  28.8  1  HAL 10 mg, CDM 2.3 mg 
2  M  26  yes  200 200 7.5 22.5 1 
HAL 6.5 mg, LI 600 mg, 
VPA 1000 mg, IMI 50 mg 
3 F  56  no  150  100  5  15.1  3 
Nortriptiline 20 mg, LI 450 
mg, CDM 1.9 mg 
4  F  35  yes  600  600  15  0  4  HAL 15 mg, CDM 7.5mg 
5 M  42  no  100  25  5  10.9  3 
HAL 1 mg, IMI 150 mg, 
Duloxetine 60mg, CDM 2 
mg 
6 M  36  yes  300  300  5  9.4  3 
HAL 2 mg, LI 900 mg, 
CDM 1.15 mg 
7  F  39  yes  150  137.5  5  3.3  3  HAL 2 mg 
P: patient; HAL: Haloperidol; VPA: Sodium Valproate; LI: Lithium; IMI: Imipramine; CDM: Clordemethyldiazepam. Aripirazole-clozapine Combination in Psychotic Mood Disorders  Clinical Practice & Epidemiology in Mental Health, 2010, Volume 6    33 
provement in negative symptomatology (respectively 40%, 
and 31%).  
Concomitant administration of aripiprazole and clozapine 
did not result in an increase in side effects over the period of 
treatment, whereas the appetite decreased in two patients.  
Plasma Levels of Drugs 
Table 2 displays serum levels of clozapine and norclo-
zapine before and after augmentation with aripiprazole. The 
mean plasma concentrations of clozapine and norclozapine at 
T1 (236.2±144.3 ng/ml and 190.9 ±167.2 ng/ml, respec-
tively) did not differ significantly from those measured at T2 
(241.1±102.4 ng/ml and 130.8±49.4 ng/ml, respectively).  
The same results were obtained after dose normalization 
of plasma concentrations of both clozapine and norclozapine 
(1.1±1.0 and 1.0±0.9 at T1, and 1.2±0.8 and 0.8±1.1 respec-
tively), which was introduced to reduce the interpatient vari-
ability because of the different dosages of clozapine.  
Finally, the clozapine/norclozapine ratio at T2 
(1.95±1.00) remained unchanged in comparison with that 
calculated at T1 (1.87±1.22), suggesting that an influence of 
aripiprazole on clozapine metabolism should be excluded. 
In the remaining patients, aripiprazole plasma levels 
ranged from 28.4 up to 103.4 ng/ml, achieving a mean value 
of 51.7±27.9 ng/ml. 
DISCUSSION 
The present study suggests that the augmentation of clo-
zapine with aripiprazole may allow a better control of at least 
some symptoms in the subjects suffering from schizoaffec-
tive and severe psychotic bipolar disorders, who failed to 
respond to the second-generation antipsychotic clozapine.  
The pivotal aspect of the study was that, an augmentation 
strategy was evaluated in difficult-to-treat psychotic patients, 
for whom the benefit of treatment was relatively smaller than 
expected. Psychotic bipolar and schizoaffective patients re-
sistant to mood stabilizers may need long-term treatment 
with atypical antipsychotics, including clozapine. Not with-
standing the clinical efficacy of clozapine due to its sero-
toninergic and dopaminergic activity leads to significant 
clinical improvement [23], the drug does not provide a com-
plete remission of positive or negative symptoms in a sub-
stantial percentage of patients [24, 25, 26, 6, 27, 28], and 
augmentation strategies are required.  
After aripiprazole augmentation all patients improved 
significantly in BPRS total scores, and particularly in 
“positive symptoms” and “negative symptoms” factors. Two 
out of 7 patients (28.57%) substantially ameliorated and 4 
(57.14%) patients slightly improved. Given the small sample 
size, including patients with a severe clinical course, these 
findings  may be considered clinically promising. A larger 
sample size and a longer follow-up evaluation could allow to 
estabilish, whether improvements diminish, are maintained, 
or even increase over time. 
A possible pharmacokinetic interaction between clozap-
ine and aripiprazole did not account for the improved clinical 
benefit obtained because dose-normalized plasma levels of 
both clozapine and norclozapine did not change, and the clo-
zapine/norclozapine metabolic ratio was unchanged in all 
patients. Therefore, the amelioration in BPRS and CGI 
scores could be due to the particular mechanism of action of 
aripiprazole [29]. In fact, the drug acts as a D2 partial agonist 
displaying a 30-40% activity of a full D2 agonist, while it is 
able to occupy more than 95% of D2 receptor [30]. There-
fore, aripiprazole exerts a total inhibitory effect on nearly 
65% of D2 receptors, but sparing the dopaminergic projec-
tions from a deep inhibitory control, despite its high affinity 
against these receptors [31, 29]. These characteristics of 
aripiprazole lead to a controlled and ameliorated firing in a 
hypodopaminergic environment created by the clozapine-
induced reduction of dopamine hyperactivity. This pharma-
codynamic interaction may result in the decrease in symp-
toms, such as emotional withdrawal, motor retardation, 
blunted affect and disorientation [10].  
The majority of studies did not report any specific side 
effects with the combination of clozapine and aripiprazole. 
Table 2. Serum Concentrations (ng/m) and Ratio Concentration/Daily Dosages of Clozapine, Norclozapine, and Serum Concentra-
tions (ng/m) of Aripiprazole at T1 and T2  (N=7) 
T1 T2 
SC C/D SC  C/D  P 
CLZ  Nor CLZ  CLZ  Nor CLZ  CLZ  Nor CLZ  CLZ  Nor CLZ 
Aripiprazole SC 
1  75.2 364.1  0.13  0.61  220.8  181.6  0.42  0.35  29.3 
2  378.5 92.3 1.89  0.46  344.7 95.6  0.72  0.48  103.4 
3  436.1 481.0 2.91  3.21  225.5 198.2  2.26  1.98  28.4 
4  269.4 116.8 0.45  0.19  353.1 157.0  0.59  0.26  39.3 
5  93.3 44.0  0.93 0.44  49.7 64.3  2.00 2.57  47.1 
6  286.3 176.5 0.95  0.59  212.9 120.8  0.71  0.40  38.1 
7  114.6 61.8 0.76  0.41  281.1 97.8  2.04  0.71  76.3 
P: patient; SC : Serum Concentration; C/D: Ratio concentration/daily dosages; CLZ: clozapine; NorCLZ: norclozapine. 34    Clinical Practice & Epidemiology in Mental Health, 2010, Volume 6  Benedetti et al. 
However, two cases of dyskinesia and malignant neuroleptic 
syndrome were reported in a sample of 26 patients [32].  
In our sample, the augmentation of clozapine with 
aripiprazole resulted safe. In fact, no side effects occurred 
after the augmentation with aripiprazole as assessed with 
DOTES Scale, if a reduction of appetite in two patients is 
excluded. Particularly, patients underwent a close EKG 
monitoring because of the potential cardiotoxicity of the an-
tipsychotic association, but no cardiologic adverse events 
were apparent. However, one patient discontinued the treat-
ment with aripiprazole because motor agitation occurred. It 
was not clear, whether this was due to the natural course of 
illness or to the combined action of aripiprazole administra-
tion and the reduction of clozapine dosage. However, psy-
chomotor activation in this case was limited to a short time 
frame and did not influence negatively illness course.   
Moreover, in our study, which enrolled patients with a 
diagnosis of affective disorders, apparently at higher risk for 
treatment-emergent extrapyramidal symptoms (EPS) as 
compared to patients with schizophrenia [33], no extrapyra-
midal side effects were observed during the combination 
treatment. Finally, in the literature, there is a growing body 
of evidence concerning the increased risk of cardiac toxicity 
and the use of older and newest antipsychotics, as well as 
clozapine [34]. Because of that issue, our patients underwent 
a careful cardiac evaluation before treatment and during fol-
low up visits, but none of them experienced signs or symp-
toms of cardiac toxicity (i.e., arrhythmias). Therefore in the 
present study, that kind of adverse reactions was not ob-
served, but it is still strongly recommended a close monitor-
ing of patient’s health conditions. 
CONCLUSIONS  
In conclusion, despite substantial limitations represented 
by the retrospective design, the small sample size, and the 
short period of follow-up, results from the present study sug-
gest that the augmentation of clozapine with aripirazole may 
be safe and effective in schizoaffective or severe psychotic 
bipolar disorders, which failed to respond to clozapine. 
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